-agonists, 586

for AECOPD, 1408

for hyperkalemia, 587t

and hypokalemia, 583t

Betaxolol (Betoptic), 1151

adverse effects of, 1158

alternative therapy, 1158

initial therapy, 1157

patient education, 1157

Bethanechol, 1974, 2163t

prokinetic agents, 508

Betoptic (see Betaxolol)

Bevacizumab (Avastin), 469t, 1972, 1991–1992, 2064, 2064t, 2065

for colon cancer, 2073, 2078

and hypertension, 1990

for metastatic colorectal cancer, 1169

Bexarotene, 470t, 942t

Biaxin (see Clarithromycin)

Bicalutamide, 2090, 2093

Bicarbonate (sodium bicarbonate), 643, 977

adverse effects of, 361

-carbonic acid system, 611

hyperkalemia and, 586, 587t

in metabolic acidosis, 562–563

for preventing SRMB, 515t

for salicylate toxicity, 70

for TCA toxicity, 77–78

BiDil (see Isosorbide dinitrate (BiDil))

Biguanide (Metformin)

adverse effects of, 1112

contraindications and precautions of, 1112–1113

dosage and clinical use of, 1113

drug interactions, 1113

efficacy of, 1113

mechanism of action, 1112–1113

pharmacokinetics of, 1112

for polycystic ovary syndrome, 1012t

for type 2 diabetes, 1140

Bile acid resins

adverse effects, 127

clinical pearls, 127

drug interactions, 127

efficacy, 127

mechanism of action, 126, 126f

pharmacokinetics/pharmacodynamics, 127

place in therapy, 127

Bilirubin, 30, 30f

blood chemistry reference values for, 19t

Bimatoprost (Lumigan), 1151

for ocular hypertension, 1151

Biperiden

for Akathisia, 1800t

for Parkinsonism, 1799

Biphosphonates, for hypercalcemia, 589t, 590

Bisacodyl, 2159t

for end-of-life care, 87

Bismuth salt, 486, 496–497

Bismuth subsalicylate (BSS)

for gastroenteritis, 2161

for Helicobacter pylori, 493–494t

for infectious diarrhea, 1449

Bisoprolol

in HFrEF, 287–288

in hypertension, 159t

Bisphosphonates, 2038, 2283–2284, 2286–2287

and dyspepsia, 487

GERD and, 503t

for osteoporosis, 2271

for prostate cancer, 2096

Bivalirudin, 254

for ACS, 239t

for heparin-induced thrombocytopenia, 178

in patients with HIT, 657

Black cohosh (Cimicifuga racemosa), 1030

Blenoxane (see Bleomycin)

Bleomycin (Blenoxane), 469t, 1978t, 1982t, 1987, 1991t, 1993, 1994t, 1995, 1977, 2040t

gonadal toxicity of, 1998

for HL, 2041

Boceprevir, 120t, 128

for HAV, 1687

Bonine (see Meclizine)

BOOSTRIX, 1357

Borates, 1626

Boric acid, for VVC, 1526

Bortezomib (Velcade), 469t, 2037t, 2038

neurotoxicity of, 1985t

peripheral nerve toxicity of, 1986

plus dexamethasone, 2037t

Bosentan, 924, 942t

for pulmonary HTN, 266

Bosutinib, 470t

Botulinum toxin A, 1271t, 1272

BranchAmin, 794t

Brentuximab vedotin, 469t

Breo Ellipta (fluticasone furoate/vilanterol), for chronic asthma, 396

Brevibloc (see Esmolol)

Brexpiprazole (Rexulti), 1789, 1791t

for Akathisia, 1799

Brimonidine (Alphagan), 1152

Brinzolamide (Azopt), 1152

Brisdelle (see Paroxetine mesylate)

Bromocriptine (Parlodel), 1250t, 1254t, 2266

and lactation, 1000

for type 2 diabetes, 1131

B

r

o

n

c

h

o

d

i

l

a

t

o

r

s

,

fo

r

C

O

P

D

,

4

1

6

–

4

1

7

,

4

2

3

B

S

S

(

s

e

e

B

i

s

m

u

t

h

s

u

b

s

a

l

i

c

yl

a

t

e

(

B

S

S

)

)

B

u

d

e

s

o

n

i

d

e

,

4

4

1

t

fo

r

a

lle

r

g

ic

r

h

init

is

,

4

4

2

fo

r

B

P

D

,

2

1

7

6

fo

r

c

hr

o

nic

a

s

thma

,

3

9

5

,

3

9

6–

3

9

7

fo

r

C

O

P

D

,

4

2

0

t

fo

r

in

fla

mma

t

o

r

y

b

o

w

e

l

dis

e

a

s

e

,

5

2

1

t

B

u

d

e

s

o

n

i

d

e

/

fo

r

m

o

t

e

r

o

l

(

S

y

m

b

i

c

o

rt

)

,

3

9

6

B

u

m

e

t

a

n

i

d

e

,

5

8

0

,

6

4

7

fo

r

H

F

,

2

7

7

B

u

p

i

v

a

c

a

i

n

e

,

1

1

7

7

t

B

u

p

r

e

n

o

rp

h

i

n

e

,

1

1

8

7

t

do

s

a

g

e

o

f,

1

1

9

9

t

fo

r

op

io

id

w

ith

dr

a

w

a

l

s

yn

dr

o

me

,

1

8

7

8

,

1

8

7

9

p. 2

2

9

3

p. 2

2

9

4

B

u

p

r

o

p

i

o

n

,

1

8

2

7

fo

r

A

D

H

D

,

1

8

7

1

fo

r

d

e

p

r

e

s

s

iv

e

dis

o

r

d

e

r

s

,

1

8

1

9

t

,

1

8

2

0

t

,

1

8

2

1

t

fo

r

dia

b

e

t

e

s

,

2

2

2

6

t

B

u

p

r

o

p

i

o

n

/z

o

n

i

s

a

m

i

d

e

E

R

,

7

6

4

fo

r

b

ip

o

la

r

d

e

p

r

e

s

s

io

n

,

1

8

3

7

a

n

d

s

le

e

p

,

1

7

7

4

fo

r

s

mo

kin

g

c

e

s

s

a

t

io

n

,

1

9

0

9

s

u

s

t

a

in

e

d

-

r

e

le

a

s

e

,

1

9

1

4

,

1

9

1

9

,

1

9

2

0–

1

9

2

2

,

1

9

2

4

B

u

S

p

a

r

(

s

e

e

B

u

s

p

i

r

o

n

e

)

B

u

s

p

i

r

o

n

e

(

B

u

S

p

a

r)

,

1

0

2

7

t

,

1

7

3

8

t

,

1

7

3

9

,

1

7

4

0

,

1

7

4

6

v

s. b

e

nz

o

dia

z

e

p

in

e

s

,

1

7

4

6

a

n

d

e

ld

e

r

ly

,

1

7

3

9

fo

r

P

M

D

D

,

1

0

2

5

B

u

s

u

l

fa

n

(

B

u

s

u

l

fe

x

,

M

yl

e

r

a

n

)

,

4

6

9

t

,

4

7

0

t

,

1

9

9

4

t

,

1

9

9

6

t

B

u

t

e

n

a

fi

n

e

,

1

6

2

4

t

B

u

t

o

c

o

n

az

o

l

e

,

1

6

2

4

t

fo

r

V

V

C

,

1

5

2

5

t

B

u

t

y

r

o

p

h

e

n

o

n

e

,

1

7

8

9

t

CC

a

b

azi

t

a

x

e

l

(

J

e

v

t

a

n

a)

,

4

6

9

t

p

e

r

ip

h

e

r

a

l

n

e

r

v

e

t

o

x

ic

ity

o

f,

1

9

8

6

fo

r

p

r

o

s

t

a

t

e

c

a

n

c

e

r

,

2

0

9

5

C

a

b

o

z

a

n

t

i

n

i

b

,

4

7

0

t

C

a

ffe

i

n

e

,

7

6

5

t

,

9

4

2

t

fo

r

a

p

n

e

a

,

2

1

8

9

fo

r

B

P

D

,

2

1

9

0

drug

int

e

r

a

c

t

io

n

w

ith

s

mo

kin

g

,

1

9

0

6

t

a

n

d

h

e

a

r

tb

ur

n

,

9

7

7

fo

r

I

D

H

,

6

5

7

a

n

d

lith

ium

,

1

8

4

3

t

a

n

d

p

r

e

gn

a

n

c

y

,

9

7

0

“

C

a

i

n

e

”

a

n

e

s

t

h

e

t

i

c

s

,

8

2

2

t

C

a

l

a

m

i

n

e

l

o

t

i

o

n

,

8

2

1

Calcijex, 622

Calcimimetics, 622–623

Calcineurin inhibitors, 635–636, 721–722

for FSGS patients, 628–629

induced nephrotoxicity, 729

Calcipotriene, for psoriasis, 835t, 837–838

Calcitonin, 2277t, 2284

for hypercalcemia, 589t, 590

for osteoporosis, 2271

Calcitriol, 621–622

for psoriasis, 835t, 838

Calcium, 26–27, 1986

blood chemistry reference values for, 18t

and BP, 134

and children, 2140t

for endometriosis, 1021

homeostasis, 586–587

hypercalcemia, 588–591

for PMS, 1024

and pregnancy, 968

recommended daily allowance, 969

and respiratory alkalosis, 1672

role of, 586

Calcium acetate, 620t

Calcium carbonate, 620t

Calcium-channel blockers (CCBs), 171, 211, 918, 993

for ACS, 239t

for AF, 314

in anginalsyndromes, 216t

CAD and, 147

diabetes and, 155–156

dihydropyridines, 155

GERD and, 503t

hemodynamic and electrophysiologic profile, 223t

for HF, 271–272

for hypertension, 140, 155–156, 156t

for hyperthyroidism, 1057, 1059t

nondihydropyridines, 155

in patients with CKD, 617

for pregestational diabetes, 979

for PSVT, 320

for thyroid storm, 1067

vasospastic and classic exertional angina, 222

Calcium gluconate, 587t

Campath (see Alemtuzumab)

Camphor, 1626, 1627

Canagliflozin, 1129–1130

Canakinumab, 903, 913

Canasa, 523t

Candesartan, 1242

for HF, 271, 283

for hypertension, 154t

Candicidin, 1626

Cangrelor, 246–247t

for ACS, 239t

for thrombotic events reduction, 244

Cannabinoids, 1224

for CINV, 473

Cannabis, 1783, 1783t

Canrenone, 581

Canthaxanthin, 856

Capecitabine (Xeloda), 470t, 1978t, 1991t

Capoten (see Captopril)

Capreomycin, for tuberculosis, 1430t

Caprylic acid, 1626

Capsaicin, 1187t

for neuropathic pain, 1188

for OA, 869

Capsaicin cream, 1182t

for PHN, 1654

Capsaicin patch, 1182t, 1654

Captopril (Capoten), 171, 257, 281–282, 281t, 336t, 2223

for BP, 339

and hyperkalemia, 584–585

in hypertension, 153t

Carba, 822t

Carbachol (Isopto Carbachol), 1152

Carbamazepine (CBZ), 42, 58, 58t, 214, 942t, 1181t, 1187t, 1279t, 1284t, 1743, 1754, 1837, 2261t

for acute mania, 1844–1845

autoinduction of metabolism of, 1282

bioequivalence of generic dosage of, 1282

for bipolar disorder, 1849t

for epilepsy, 57

extended-release forms of, 1282

for HAV, 1688

and hematologic toxicity, 1281

hepatotoxicity with, 1281–1282

initiation and dosage of, 1281

lamotrigine and, 1286–1287

and lithium, 1843t

for nocturnal leg cramps, 173

for ocular emergencies, 1160t

pharmacokinetics of, 1282

for schizophrenia, 1809

for seizures, 1281–1282

teratogenic effects, 973t

valproate and, 1296

Carbapenem

for febrile neutropenia, 1561

for skin and soft tissue infections, 1552

for UTI, 1497t

Carbidopa–levodopa (enteral suspension) (Duopa), for Parkinson’s disease, 1250t

Carbidopa–levodopa (CR) (Sinemet CR), for Parkinson’s disease, 1250t, 1260

Carbidopa–levodopa (ER) (Rytary), for Parkinson’s disease, 1250t, 1260–1261

Carbidopa–levodopa ODT (Parcopa), for Parkinson’s disease, 1250t

Carbonyl iron, 1930

Carboplatin (Paraplatin), 469t, 475, 1991t, 2065

for blood progenitor cell rescue, 2005

for NSCLC, 2062t, 2063t, 2064t

for SCLC, 2068t

Carboprost tromethamine, for postpartum hemorrhage, 997–998, 997t

Cardene IV (see Nicardipine)

Cardiac resynchronization therapy (CRT), 272

Carfilzomib, 469t, 2038

Cariprazine (Vraylar), 1797t, 1845

for acute mania, 1845t

for schizophrenia, 1789, 1791t

Carisoprodol, 1186t

Carmustine (BiCNU), 469t, 1979t, 1987, 1991, 1991t, 1994t, 1996, 1996t

and cranial neuropathies, 1987

Carteolol (Ocupress), 1151

Carvedilol, 258

in HFrEF, 287

for hypertension, 158–159, 159t

in peri-infarction period, 253, 258

Caspofungin, 1569, 1624t, 1625, 1632, 1633, 1634, 1640, 1641

adverse effects of, 1334t

dosing of, 1336t

for fungal endocarditis, 1400

renal failure, dosing of drugs, 675

Catapres (see Clonidine)

Catechol-O-methyltransferase inhibitors (COMT), 1262–1264

pharmacologic and pharmacokinetic properties of, 1263t

Catecholamines, for septic shock, 371

Cathelicidins, 1626

CBZ (see Carbamazepine (CBZ))

CCBs (see Calcium-channel blockers (CCBs))

p. 2294

p. 2295

Ceclor (see Cefaclor)

Cedax (see Ceftibuten)

Cefaclor (Ceclor), 1325t

for chronic antimicrobial therapy, 1499t

for UTI, 1489t

Cefadroxil (Duricef), 1325t

Cefamandole (Mandol), 1325t

Cefazolin (Ancef), 658, 661, 662, 1165, 1325t, 1548

for aerobic gram-positive cocci, 1326t

for anaerobes, 1328t

for CAPD-associated peritonitis, 1476t

dosing of, 1336t

for gram-negative aerobes, 1327t

for PVE, 1392t

for pyelonephritis, 995

renal failure, dosing of drugs, 675–676

for skin and soft tissue infections, 1548

for surgical procedures, 1345t, 1346, 1348–1349

for UTI, 1497t

Cefdinir (Omnicef), 1325t

Cefditoren (Spectracef), 1325t

Cefepime (Maxipime), 1325t

for aerobic gram-positive cocci, 1326t

for anaerobes, 1328t

for CAPD-associated peritonitis, 1476t

for CNS infections, 1373t

for cystic fibrosis, 461t

dosing of, 1336t

for febrile neutropenia, 1561

for gram-negative aerobes, 1327t

for gram-negative bacillary meningitis, 1378

for skin and soft tissue infections, 1550

for UTI, 1497t

Cefixime (Suprax), 1325t

for disseminated gonococcal infection, 1514

for shigellosis, 1456

for typhoid fever, 1456

for uncomplicated gonorrhea, 1508

Cefizox (see Ceftizoxime)

Cefonicid (Monocid), 1325t

Ceforanide (Precef), 1325t

Cefotaxime (Claforan), 1325t

for anaerobes, 1328t

and biliary pseudolithiasis, 1375

for CNS infections, 1373t

for NEC, 2183

for sepsis, 2186t

for UTI, 1497t

Cefotetan (Cefotan), 1325t

for anaerobes, 1328t

for chorioamnionitis, 996

for PID, 1512–1513t

Cefoxitin (Mefoxin), 1325t

for chorioamnionitis, 996

for PID, 1512–1513t

for surgical procedures, 1345t

for UTI, 1497t

Cefpodoxime proxetil (Vantin), 1325t

for UTI, 1489t

Cefprozil (Cefzil), 1325t

Ceftaroline (Teflaro), 1325t, 1371, 1393

for aerobic gram-positive cocci, 1326t

for gram-negative aerobes, 1327t

for skin and soft tissue infections, 1549

for UTI, 1497t

Ceftazidime (Fortaz), 462, 661, 663, 671, 1325t

for anaerobes, 1328t

for CAPD-associated peritonitis, 1476t

for cystic fibrosis, 461t

dosing of, 1336t

for febrile neutropenia, 1561

for gram-negative aerobes, 1327t

for gram-negative bacillary meningitis, 1378

renal failure, dosing of drugs, 667–668

for skin and soft tissue infections, 1550

for UTI, 1497t

Ceftazidime-avibactam, 1327t

Ceftibuten (Cedax), 1325t

Ceftin (Cefuroxime axetil), 1325t

Ceftizoxime (Cefizox), 1325t

for anaerobes, 1328t

for CAPD-associated peritonitis, 1476t

Ceftolozane/tazobactam (Zerbaxa), 1325t, 1371, 1401

for gram-negative aerobes, 1327t

Ceftriaxone (Rocephin), 549, 690, 1325t, 1371, 1376, 1401, 1720, 1723, 2131t

and aminoglycoside, 1390

for anorectal gonorrhea, 1511

and biliary pseudolithiasis, 1375

for CNS infections, 1373t

for disseminated gonococcal infection, 1514

dosing of, 1336t

for endocarditis, 1390

for neonatal DGI, 1514

for skin and soft tissue infections, 1549

for tularemia, 1723

for typhoid fever, 1455

for uncomplicated gonorrhea, 1508t, 1509

for UTI, 1497t

Cefuroxime (Zinacef), 1325t, 2131t

for aerobic gram-positive cocci, 1326t

for gram-negative aerobes, 1327t

for N. meningitides, 1374

for UTI, 1497t

Cefuroxime axetil (Ceftin), 1325t, 1720

Cefzil (see Cefprozil)

Celecoxib, 55, 490, 707, 870–871, 870t, 887, 888t

Celexa (see Citalopram)

Central α2

-agonists, for hypertension, 140

Cephalexin (Keflex), 977, 1325t

for chronic antimicrobial therapy, 1499t

for pyelonephritis, 977

for skin and soft tissue infections, 1547

for UTI, 1489t

Cephalosporins, 662, 685–686, 1372, 1720, 1725

adverse effects of, 1332t

for cardiac surgery prophylaxis, 1391–1392

for chorioamnionitis, 996

for CNS infections, 1373t

during pregnancy, 977

for tularemia, 1725

for uncomplicated gonorrhea, 1508t, 1509

for UTI, 1497t

Cephalothin, 661, 662

Ceritinib, 470t

Certolizumab

for CD, 529

pegol, 524, 881, 882, 895, 896t

for inflammatory bowel disease, 522t

Cerubidine (see Daunorubicin)

Cervarix, 1359

Cesamet (see Nabilone)

Cetilistat, 764

Cetirizine (Zyrtec), 433t

fo

r

r

h

init

is

,

4

3

7

a

n

d

s

le

e

p

,

1

7

6

6

C

e

t

u

x

i

m

a

b

(

E

rb

i

t

u

x

)

,

4

6

9

t

,

1

9

8

3

t

,

2

0

6

4

,

2

0

6

5

fo

r

c

o

lo

n

c

a

n

c

e

r

,

2

0

7

3

C

e

v

i

m

e

l

i

n

e

,

1

9

7

4

C

h

a

s

t

e

b

e

r

ry

(

Vi

t

e

x

a

g

n

u

s

-

c

a

s

t

u

s

o

r

VA

C

)

,

1

0

2

4

C

h

E

I

s

(

s

e

e

C

h

o

l

i

n

e

s

t

e

r

a

s

e

i

n

h

i

b

i

t

o

r

s

(

C

h

E

I

s

)

)

C

h

e

m

o

p

r

o

p

h

yl

a

x

i

s

,

fo

r

O

I

s

,

1

5

9

8

C

h

e

m

o

t

h

e

r

a

p

y

a

c

n

e

ifo

r

m–

e

r

yth

e

ma

t

o

u

s

r

a

s

h

,

1

9

7

8

fo

r

a

c

ut

e

le

uke

mia

,

1

9

9

7

fo

r

a

c

ut

e

my

e

lo

id

le

uke

mia

,

1

9

9

7

fo

r

a

c

ut

e

tub

ula

r

o

b

s

tru

c

t

io

n

,

1

9

9

2

fo

r

a

g

gr

e

s

s

iv

e

lymp

h

o

ma

s

,

2

0

4

2

in

A

L

L

,

2

0

1

6

,

2

0

1

7

t

a

n

d

a

lop

e

c

ia

,

1

9

7

6–

1

9

7

7

fo

r

A

M

L

,

2

0

2

6

a

n

d

a

n

e

mia

,

1

9

7

2

fo

r

a

r

r

hythmia

s

,

1

9

9

0

fo

r

a

ut

o

n

o

mic

n

e

ur

op

a

thy

,

1

9

8

7

fo

r

B

-

c

e

ll

lymp

h

o

ma

,

2

0

2

0–

2

0

2

1

o

n

b

o

n

e

ma

r

r

o

w

,

1

9

6

9

–

1

9

7

3

fo

r

c

a

r

dio

my

op

a

thy

,

1

9

8

7

–

1

9

8

8

a

n

d

c

a

r

dio

t

o

x

ic

ity

,

1

9

8

7

–

1

9

9

0

a

n

d

c

o

lo

ny

-

s

t

imula

t

in

g

fa

c

t

o

r

s

,

1

9

7

0–

1

9

7

1

a

n

d

c

r

a

nia

l

n

e

r

v

e

t

o

x

ic

ity

,

1

9

8

7

c

yt

o

t

o

x

ic

e

ffe

c

t

s

,

1

9

7

0

d

e

r

ma

t

o

lo

g

ic

imp

a

c

t

s

,

1

9

7

3

–

1

9

7

6

a

n

d

dia

r

r

h

e

a

,

1

9

7

6

do

s

a

g

e

r

e

g

ime

n

fo

r

intr

a

th

e

c

a

l,

2

0

1

6

t

do

s

in

g

in

in

fa

nt

s

a

n

d

y

o

un

g

c

h

ildr

e

n

,

2

0

0

7

a

n

d

dr

y

s

kin

,

1

9

7

8

a

n

d

e

s

op

h

a

g

it

is

,

1

9

7

5

a

n

d

e

s

op

h

a

gu

s

,

1

9

7

5

a

n

d

filgr

a

s

t

im

,

1

9

7

1

,

1

9

7

2

a

n

d

GI

tr

a

c

t

,

1

9

7

3

–

1

9

7

6

a

n

d

h

a

n

d

-

fo

o

t

s

yn

dr

o

me

,

1

9

7

8

h

e

ma

t

o

lo

g

ic

e

ffe

c

t

s

,

1

9

6

9

–

1

9

7

3

a

n

d

h

e

mo

r

r

h

a

g

ic

c

y

s

t

it

is

,

1

9

9

2

–

1

9

9

3

fo

r

H

L

,

2

0

4

1

hyp

e

r

s

e

n

s

it

iv

ity

r

e

a

c

t

io

n

s

,

1

9

8

0–

1

9

8

4

a

n

d

hyp

e

r

t

e

n

s

io

n

,

1

9

9

0

fo

r

in

do

le

nt

N

H

L

s

,

2

0

4

4

in

du

c

t

io

n

c

o

mb

in

a

t

io

n

,

2

0

1

4–

2

0

1

5

int

e

r

a

c

t

io

n

w

ith

r

a

dia

t

io

n

th

e

r

a

p

y

,

1

9

7

8

–

1

9

7

9

,

1

9

7

8

t

p. 2

2

9

5

p. 2

2

9

6

intr

a

th

e

c

a

l

p

r

op

hy

la

x

is

,

2

0

1

5

–

2

0

1

6

ir

r

it

a

nt

a

n

d

v

e

s

ic

a

nt

r

e

a

c

t

io

n

s

,

1

9

7

9

–

1

9

8

0

fo

r

la

r

g

e

c

e

ll

lymp

h

o

ma

s

,

2

0

2

1

a

n

d

life

-

thr

e

a

t

e

nin

g

n

e

utr

op

e

nia

,

1

9

7

0

lo

n

g

-

t

e

r

m

c

o

mp

lic

a

t

io

n

s

,

1

9

9

7

–

1

9

9

9

for lymphoblastic (T-cell) lymphoma, 2019–2020

and mucositis, 1974–1975

and myelosuppression, 1970–1972

and myocardial infarction, 1990

nausea and vomiting, 1973

nephrotoxicity, 1990–1992, 1991t

for neuroblastoma, 2003–2006

neurotoxicity, 1984–1987, 1985t

and neutropenia, 1970–1971

for NSCLC, 2063–2064

and oral cavity complications, 1973–1975

for osteosarcoma, 2008–2010

ototoxicity, 1987

for pediatric ALL, 2014

and pegfilgrastim, 1971

peripheral nerve toxicity, 1986

and peripheral neuropathy, 1986–1987

and pigment changes, 1977

and proteinuria, 1991–1992

and pulmonary functions, 1993–19936

for rhabdomyosarcoma, 2010–2011

skin and nail changes, 1977–1978

for specific organs, 1984–1987

and stomatitis, 1974–1975

and thrombocytopenia, 1970, 1972

venous thrombotic events, 1972–1973

and Wilms tumor, 2006–2008

and xerostomia, 1973–1974

Chitosan, 765t

Chlor-Trimeton (see Chlorpheniramine)

Chlorambucil (Leukeran), 470t, 1994t

for CLL, 2033

Chloramphenicol (Chloromycetin), 1325t, 1720

adverse effects of, 1333t

for RMSF, 1725

for tularemia, 1725

Chlordiazepoxide, 1737t